Stock Fundamentals

Company Information

Company Name
Taysha Gene Therapies Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US8776191061
CIK: 0001806310
CUSIP: 877619106
Currency: USD
Full Time Employees: 99
Phone: 214 612 0000
Fiscal Year End: December
IPO Date: Sep 24, 2020
Description:

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Address:

3000 Pegasus Park Drive, Dallas, TX, United States, 75247

Directors & Officers

Name Title Year Born
Mr. Sean P. Nolan CEO & Chairman 1968
Dr. Sukumar Nagendran M.D. President, Head of Research & Development and Director 1967
Mr. Kamran Alam CPA, M.B.A. CFO & Corporate Secretary 1978
Hayleigh Collins Director of Corporate Communications & Investor Relations NA
Mr. Frederick Porter Ph.D. Chief of Staff & Technical Operations Officer NA
Ms. Emily McGinnis M.P.H. Chief Patient & External Affairs Officer NA
Mr. Sean McAuliffe Chief Business Officer NA
Dr. Steven Gray Ph.D. Chief Scientific Advisor of UT Southwestern Gene Therapy Program NA
Berge Minassian M.D. Chief Medical Advisor of UT Southwestern Gene Therapy Program NA
Ms. Rumana Haque-Ahmed Chief Regulatory Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 10, 2026 Sukumar Nagendran N/A Sale 200.00K $4.46 $892.00K
Feb 04, 2026 Kamran Alam N/A Sale 1.66K $4.52 $7.48K
Jan 26, 2026 Kamran Alam N/A Sale 23.85K $4.61 $109.94K
Jan 26, 2026 Sean P Nolan N/A Sale 41.31K $4.61 $190.45K
Jan 26, 2026 Sukumar Nagendran N/A Sale 26.92K $4.61 $124.09K
Jan 23, 2026 Kamran Alam N/A Sale 78.97K $4.75 $375.10K
Jan 23, 2026 Sean P Nolan N/A Sale 136.79K $4.75 $649.75K
Jan 23, 2026 Sukumar Nagendran N/A Sale 89.13K $4.75 $423.38K
Jan 12, 2026 Sukumar Nagendran N/A Sale 200.00K $4.71 $942.00K
Dec 01, 2025 Sukumar Nagendran N/A Sale 260.05K $4.51 $1.17M
Nov 28, 2025 Sukumar Nagendran N/A Sale 110.13K $4.75 $523.09K
Sep 10, 2025 Sukumar Nagendran N/A Sale 200.00K $3.23 $646.00K
May 30, 2025 Paul B Manning N/A Purchase 750.00K $2.75 $2.06M

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
RA Capital Management, LLC 23.56M Mar 31, 2026 8.20% $1.12 0.00%
The Goldman Sachs Group Inc 22.37M Mar 31, 2026 7.79% $0.01 63.37%
venBio Select Advisor LLC 21.70M Mar 31, 2026 7.55% $0.95 0.00%
BlackRock Inc 18.37M Mar 31, 2026 6.39% $0.00 -1.49%
Vestal Point Capital LP 18.00M Mar 31, 2026 6.26% $2.25 30.91%
Morgan Stanley - Brokerage Accounts 17.97M Mar 31, 2026 6.25% $0.00 -0.63%
FMR Inc 14.32M Mar 31, 2026 4.98% $0.00 5.86%
RTW INVESTMENTS, LLC 13.68M Mar 31, 2026 4.76% $0.61 -16.58%
Vanguard Group Inc 13.27M Dec 31, 2025 4.62% $0.00 3.25%
State Street Corp 11.21M Mar 31, 2026 3.90% $0.00 3.88%
Octagon Capital Advisors LP 8.86M Mar 31, 2026 3.08% $4.38 0.00%
Siren, L.L.C. 8.83M Mar 31, 2026 3.07% $1.09 -12.83%
Polar Capital Holdings PLC 5.65M Mar 31, 2026 1.97% $0.09 -28.71%
Geode Capital Management, LLC 5.53M Mar 31, 2026 1.93% $0.00 2.69%
D. E. Shaw & Co LP 4.43M Mar 31, 2026 1.54% $0.01 10.31%
Baker Bros Advisors LP 4.00M Mar 31, 2026 1.39% $0.10 0.00%
Millennium Management LLC 3.28M Mar 31, 2026 1.14% $0.01 3.24%
Casdin Capital, LLC 3.25M Mar 31, 2026 1.13% $1.10 116.67%
ADAR1 Capital Management LLC 2.98M Mar 31, 2026 1.04% $0.78 19.38%
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND 2.88M Mar 31, 2026 1.00% $0.02 -22.53%

Shares Statistics

Shares Outstanding: 287.36M
Shares Float: 196.96M
% Insiders: 1,061.90%
% Institutions: 9,573.60%
Short % Float: 13.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 7.51M 2.62% ▲ 0.00% Apr 30, 2026
2 State Street® SPDR® S&P® Biotech ETF 6.23M 2.17% ▼ 0.71% Apr 30, 2026
3 Fidelity Growth Compy Commingled Pl S 5.45M 1.90% ▲ 0.16% Mar 31, 2026
4 Polar Capital Biotech S Inc 5.36M 1.86% ▲ 0.00% Apr 30, 2026
5 iShares Russell 2000 ETF 5.20M 1.81% ▲ 0.85% Apr 30, 2026
6 Fidelity Growth Company Fund 4.18M 1.45% ▲ 0.00% Mar 31, 2026
7 Vanguard Institutional Extnd Mkt Idx Tr 2.51M 0.87% ▲ 1.02% Apr 30, 2026
8 Fidelity Small Cap Index 2.16M 0.75% ▲ 1.14% Feb 28, 2026
9 iShares Russell 2000 Growth ETF 1.82M 0.63% ▲ 1.83% Apr 30, 2026
10 iShares Biotechnology ETF 1.66M 0.58% ▲ 1.54% Apr 30, 2026

Valuation Metrics

Enterprise Value: $1.50B
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $1.64B
EBITDA: $-131.41M
Book Value: $0.87
Earnings/Share: $-0.38
Profit Margin: 0.00%
Operating Margin: -1,774.37%
ROA (TTM): -37.77%
ROE (TTM): -97.28%
Revenue (TTM): $7.47M
Revenue/Share (TTM): $0.02
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 171.30%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 12.23x 0.20x 0.28x -1,753.94x -0.46x
2024-12-31 5.42x 0.64x 0.55x -896.66x -0.52x
2023-12-31 4.08x 0.56x 0.57x -14.49x -0.40x
2022-12-31 1.54x 41.61x 0.99x -33.18x -0.25x
2021-12-31 3.08x 0.39x 0.55x -121.34x -0.22x
2020-12-31 36.17x 0.00x 0.03x -1,535.79x 0.00x
2019-12-31 0.10x 0.00x 10.00x N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about TSHA.US!